Fig. 7. IGF1 protects CGCs from apoptosis induced by MEHP by activating the PI3K/AKT pathway. CGCs were pre-treated with 30, 50 and 100 ng/mL of insulin-like growth factor (IGF) 1, an activator of the PI3K/AKT, signaling pathway, for 2 h followed by treatment with 250 MEHP for 24 h. (A) Western blot bands represent the expression of proteins in the PI3K/AKT/Bcl-2/Bax pathway. (B~I) Each column represents the mean±SD. The mean expression in CGCs from each group is shown as a fold-change compared to the mean expression in the control group which was ascribed an arbitrary value of 1. With each time point, ^*p<0.05 vs control, ^#p<0.05 vs MEHP only treatment group (n=4).